Introduction
Gastrointestinal stromal tumor (GIST) is the most common sarcoma (1) , often originating in the stomach or the small intestine. GIST is a paradigm for targeted molecular therapy, since the majority of GISTs contain an activating mutation in exon 11 of the KIT proto-oncogene, for which there are effective and well-tolerated tyrosine kinase inhibitors (2, 3) . Imatinib mesylate, which inhibits the KIT oncoprotein, improved the median survival in patients with advanced and metastatic GIST from one to five years (3), while adjuvant imatinib improved recurrence-free survival in patients with resectable disease (4) .
Platelet derived growth factor receptor alpha (PDGFRA)-mutant GIST is the second most common form of GIST. Approximately half of PDGFRA-mutant GISTs contain a D842V substitution, which is inherently resistant to imatinib therapy (5) . The majority of PDGFRA-mutant GISTs develop in the stomach (6, 7) , while KIT-mutant GISTs can arise in the stomach, small intestine, or rectum (8) , suggesting an innate and important biologic difference between these driver mutations. Other GIST mutation types also associate with predictable clinicopathologic features. For example, KIT exon 9-mutant GISTs nearly always develop in the small intestine (9) , neurofibromin 1-mutant (NF1-mutant) GISTs have a predilection for the duodenal-jejunal flexure (10) , and succinate dehydrogenase deficient (SDH-deficient) GISTs are indolent, multifocal, and one of the few GISTs, along with those driven by kinase fusions, which metastasize via the lymphatic system (11, 12) . The underlying biologic mechanisms linking mutation type and clinicopathologic features are not well understood.
Although PDGFRA D842V (D842V)-mutant GISTs do not respond to imatinib, natural history shows that recurrence-free survival is more favorable in patients with any PDGFRA mutation when compared to a KIT mutation (4) . This finding, along with the predictable behavior of GIST mutation types, has us hypothesize that the mutational driver may impact other aspects of tumor biology, specifically the tumor microenvironment and host immune response. Our group has extensively characterized the immune infiltrate in Kit-mutant GIST using a genetically engineered mouse model and human specimens (13) (14) (15) (16) (17) , providing clear rationale for multiple immunotherapy trials in patients with GIST, but the immune response to PDGFRA-mutant GIST is currently unknown.
In this study, we performed RNA sequencing on 75 surgical specimens from 75 human GIST patients to characterize the immune infiltrates of different GIST mutations. Surprisingly, we discovered that PDGFRA-mutant GIST harbors more immune cells than KIT-mutant GIST, which may be related to oncogene-specific cytokine production or more HLA-diverse neoepitope recognition, suggesting that patients with PDGFRAmutant GIST might benefit from therapeutic immunomodulation. We trained a random forest machine learning algorithm on RNAseq data from all of our KIT and PDGFRAmutant GISTs, as well as on a subset of untreated, primary, gastric (UPG) KIT and PDGFRA-mutant GISTs, in order to characterize a PDGFRA-specific immune landscape. Finally, we identified the top immune features correlating with high PD-1 and PD-L1 expression across all GIST specimens to identify potential barriers to and synergistic opportunities for successful immune checkpoint blockade in GIST.
Results

ssGSEA identifies immune cell pathway enrichment in PDGFRA-mutant GIST.
We performed RNA sequencing and principal component analysis (PCA) of 75 human GIST specimens comprising various mutation types (n=37 KIT-mutant, n=24
PDGFRA-mutant, n=7 SDH-deficient, n=4 multiple drivers, n=2 wild type, and n=1 NF1-mutant; Supplemental Table 1 Given what our group has discovered regarding the immune infiltrate of GIST (13) (14) (15) 17) , the metabolic characteristics of imatinib-treated GIST (18) , and the association of cell cycle activity with GIST aggressiveness (19, 20) , we used our sequencing data to perform single-sample gene set enrichment analyses (ssGSEA) focused on immune, metabolic, and cell cycle pathways (Figure 1 ). Using published gene sets (21) , along with assessment of previously published metabolic, cell cycle, and immune pathways (22) , we identified 136 gene sets for inclusion in ssGSEA (Supplemental Table 2 ). ESTIMATE and Cyt scoring, which infer the quantity and cytolytic activity of the immune infiltrates respectively (23, 24) , revealed that KIT-mutant GIST had a range of immune cell infiltration and cytolytic activity (Figure 1) . Meanwhile, SDH-deficient, NF1-mutant, PDGFRA D842V (D842V)-mutant GISTs with a concurrent CDKN2A (p16) 6 deletion, and wild type GISTs (defined as non-KIT, non-PDGFRA, non-RAS activated, and non-SDH deficient as previously described (25) ) exhibited generally low ESTIMATE and Cyt scores and a lack of immune cell pathway enrichment.
Conversely, ESTIMATE, Cyt, and ssGSEA identified increased immune cell infiltration, greater immune cell activity, and a significant enrichment of immune-related gene sets in PDGFRA-mutant GISTs, an unexpected finding which suggested that PDGFRA-mutant GISTs were more immunogenic than other GIST mutations ( Figure   1 ). Cell cycle activity pathways did not clearly correlate with immune cell infiltration across all GIST driver mutation types, while metabolic activity appeared to inversely correlate with the quantity of immune infiltrate, specifically in KIT exon 11-mutant GISTs. Overall, these data show that while tumors driven by a particular GIST mutation can have variable immune profiles, PDGFRA-mutant GIST contains the strongest gene expression-based immune signature when compared to other GIST mutations.
PDGFRA mutant GIST is more immunologically active than KIT mutant GIST.
In order to validate our ssGSEA finding that PDGFRA-mutant GIST was highly enriched in immune cell quantity and cytolytic activity, we first compared the clinicopathologic characteristics of all KIT and PDGFRA-mutant GISTs (Supplemental Table 3 ; n=61). Though not associated with immune cell infiltration in GIST, tumor size, mitotic rate, and tumor location are predictive of GIST aggressiveness and recurrence free survival after surgical resection (26) . PDGFRA-mutant GISTs were more commonly found in stomach when compared to KIT-mutant GISTs, and there were significantly more males in our PDGFRA-mutant GIST cohort. There was also a trend toward decreased mitotic activity in PDGFRA-mutant when compared to KIT-mutant GISTs (Supplemental Table 3 ). ESTIMATE and Cyt scores, however, did not correlate with mitotic rate across all KIT and PDGFRA-mutant GISTs (Supplemental Figure 2A) . Cyt score and the overall number of CD45 mRNA transcripts were significantly higher in PDGFRA-mutant when compared to KIT-mutant GISTs (Figure 2A) , while there was also a trend towards increased ESTIMATE score and CD8 mRNA expression, suggesting that PDGFRA-mutant GISTs may exhibit greater immune cell infiltration and activation than KIT-mutant GISTs.
Since we observed significant differences in tumor location between KIT and PDGFRA-mutant GISTs, and metastatic lesions and treatment status have also been shown to alter the immune infiltrate in GIST (14, 27) , we then compared only untreated, primary, gastric (UPG) PDGFRA and KIT-mutant GISTs to minimize confounders and maximize the potential to observe important biologic differences that may be related to the oncogenic driver (Supplemental Table 4 ; n=22). UPG PDGFRA and KIT-mutant GISTs with a low mitotic rate exhibited significantly higher ESTIMATE scores when compared to UPG GISTs with a high mitotic rate (Supplemental Figure 2B) , suggesting that immune cell infiltration may be partly related to GIST aggressiveness when controlling for tumor location and treatment status. However, when also controlling for the mutational driver in addition to tumor location and treatment status, mitotic rate did not inversely correlate with immune cell infiltration (Supplemental Figure 2C) , implying that the oncogenic driver may also be contributing to differences in immune response. In fact, ESTIMATE score, Cyt score, and the mRNA expression of CD45 were significantly greater in UPG PDGFRA-mutant GISTs when compared to 8 UPG KIT-mutant GISTs, while the expression of CD8 mRNA was also increased ( Figure 2B) . Furthermore, gene set enrichment analyses showed that UPG PDGFRAmutant GISTs were more significantly enriched in the overall immune response, the adaptive immune response, antigen binding, and alpha/beta T cell activation pathways among others (Figure 2C) , including lymphocyte activation, lymphocyte differentiation, and B cell activity (not shown), suggesting that the difference in immune infiltration and activity may be related to the oncogenic driver.
To further validate the observed differences in immune cell infiltrate between PDGFRA and KIT-mutant GISTs, we performed immunohistochemical (IHC) staining for CD45 and CD8 on KIT and PDGFRA-mutant GISTs, including additional tumors not included in the sequencing cohort ( Figure 2D) Figure 2E ). Together, these findings confirm that PDGFRA-mutant GISTs contain more immune cells with increased cytolytic activity when compared to KIT-mutant GISTs with similar clinicopathologic features.
CIBERSORT and DGE analysis identify unique immune signatures in GIST.
To discover additional differences in the immune landscape between UPG PDGFRA and UPG KIT-mutant GISTs, we profiled a previously defined set of 117 relevant immune features (Supplemental Table 5 ) (28, 29 (30) . Furthermore, many cytokine and chemokine pathways were significantly upregulated in UPG PDGFRA-mutant GISTs (Figure 4B ), which we found to be related to increased expression of CXCL14, CCL7, CCL19, VEGFA, and KITLG ( Figure 4C ).
The differences observed in CXCL14 expression were particularly intriguing. Together, these findings suggest that CXCL14 expression may contribute to the observed differences in immune infiltration between PDGFRA and KIT-mutant GISTs (31, 32) .
PDGFRA mutation produces multiple, HLA-diverse, strong binding neoepitopes.
Given the association of neoantigen presentation with inflamed tumor/immune microenvironments in other malignancies, we hypothesized that PDGFRA-mutant
GISTs may produce more potent neoepitopes when compared to KIT-mutant GISTs. To explore this, we first mapped out the 8-, 9-, and 10-mer neoepitopes produced by all driver mutations in our cohort, generating neoepitopes with the mutation placed at each amino acid position in the mutant peptide. Then, we tested the binding affinity of each neoepitope to the matched, patient-specific HLA type in which that mutation was found.
First, we wanted to determine if total neoepitope burden and the number of high affinity neoepitopes produced by each GIST specimen correlated with immune infiltration or cytolytic activity in GIST, since neoepitope burden has been shown to correlate with increased response to immunotherapy in a variety of cancers (33, 34) .
However, total neoepitope burden and the number of high-affinity (<500nM binding) or very high-affinity (<50nM binding) neoepitopes did not correlate with immune infiltration or cytolytic activity across all mutations in the GIST cohort ( Figure 5A ) or across KIT
and PDGFRA-mutant GISTs specifically (not shown).
We observed that the majority of patients with an oncogenic mutation in PDGFRA or KIT produced at least one high-affinity neoepitope (<500 nM binding), regardless of mutation subtype ( Figure 5B ). We also found that the D842V mutation produced 34 unique, high-affinity neoepitope:HLA specific binding combinations across the predicted HLA-types in our cohort of 16 D842V-mutant patients (
Figure 5B), while KIT exon 11 and other PDGFRA mutations on average only produced 2-3 per mutation (Supplemental Table 6 ). The D842V mutation generated 6 different neoepitopes that bound to 12 different HLA types in 14 patients in our cohort (Supplemental Table 7 ), one of which is the most common HLA type in the United States and present in 95.7%
of Caucasians (HLA*A02:01) (35, 36) , suggesting that this mutation could produce an immune response in a wide variety of patients, whereas KIT exon 11 neoepitopes bound to less prevalent HLA-types.
Since the number of patients with D842V mutations (n=16) exceeded the number of patients with any individual KIT mutation (n=1 to 4, Supplemental Table 7 ) and this may obscure our HLA observations, we explored mutation-specific neoepitope binding diversity more broadly against all validated NetMHCPan3.0 HLA-types ( Figure 5C ).
Again, nearly all PDGFRA and KIT GIST mutations produced at least one high affinity neoepitope capable of binding to many different HLA-types. D842V neoepitopes bound with a very high affinity (<50 nM binding) to HLA*A02:01 and many other prevalent HLA types. Interestingly, 50% (4/8) of all PDGFRA mutations produced at least one very high-affinity neoepitope (<50nM binding) to HLA*A02:01, compared to only 14% of KIT mutations (2/14). Thus, while all KIT and PDGFRA-mutant GISTs appear to produce high-affinity neoepitopes, PDGFRA-mutant GISTs appear to produce more high-affinity neoepitopes to more common HLA types. Given that GIST is often driven by a single oncogenic mutation, and GIST harbors a rich immune infiltrate, this raises the possibility that oncogenic GIST mutations produce neoepitopes that may classify as what has recently been provocatively described as high quality neoepitopes (37) .
Machine learning identifies immune gene signatures for GIST.
Through bioinformatics prediction and biologic validation methods, it appears that
PDGFRA-mutant GIST contains more immune cells with a higher cytolytic activity than
KIT-mutant GIST, and both subsets contain a unique immune profile. This makes characterizing a global immune infiltrate in GIST challenging, and suggests that specific immunotherapy approaches may ultimately need to be targeted to the specific oncogenic mutation in GIST. We therefore sought to define the most important immune features differentiating PDGFRA and KIT-mutant GISTs through machine learning, which is an unbiased approach not dependent on previously defined gene set analysis, allowing for the discovery of novel and impartial observations. We specifically used all KIT and PDGFRA-mutant GISTs (Supplemental Table 3 ; n=61), as well as only UPG KIT and PDGFRA-mutant GISTs (Supplemental Table 4 ; n=22) to develop two random forest models, and assumed that these immune differences would most likely be related to the oncogenic driver.
The combination of salient immune features capable of most accurately profiling a PDGFRA or KIT-mutant GIST were identified based on each feature's "importance,"
which is calculated as part of caret for R's implementation of randomForest (38) . The "feature importance" metric is a measure indicating how useful a feature is for separating samples into their distinct classes. The features with the highest importance provide the classifier with the highest increase in performance.
We included all 117 immune features to initially create the model (Supplemental Table 5 ) and subsequently retrained the model using fewer features. We noted that including more features in the model increased the model's performance on the training set, but decreased the model's performance on the test set, a phenomenon known as overfitting (Supplemental Figure 3A) . Therefore, to prevent overfitting, we retrained the model using only the 6 most important features, which we believe will broaden the applicability of our model to future GIST samples. When restricting the model to the six KIT and PDGFRA-mutant GISTs, we excluded these features and retrained our random forest model, which reduced classifier performance and model accuracy from 91% to 72.7% (Supplemental Figure 3B) .
We further validated our model on an external cohort of GISTs from the CINSARC study ( (39) 
Discussion
The dramatic success of immune checkpoint blockade in a variety of notoriously difficult-to-treat cancers has nearly standardized immunomodulation as an approach for cancer treatment (40) (41) (42) . However, subsequent research has advanced our understanding of how cancer type and tumor-cell specific characteristics, such as genomic mutational burden can predict response to immunotherapy (33, 34) . It has also recently been shown that the state of the immune microenvironment can prevent response to immunotherapy if not appropriately addressed (43) . In fact, it has become clear that the complex relationship between cancer cell intrinsic factors and the subtleties of the cancer-type specific immune microenvironment may make a generalized strategy of immune checkpoint blockade ineffective (44) . Therefore, it has become increasingly evident that cancer-specific immunotherapeutic strategies are needed.
In this study, we performed RNA sequencing on 75 human GIST specimens from 75 patients to characterize the immune landscape of different GIST mutational drivers, which we believe is the largest cohort of GISTs to be analyzed with next-generation RNA sequencing. After observing potential differences in immune infiltration, we focused on the two prevalent GIST mutational subtypes, namely KIT and PDGFRA, and found that PDGFRA-mutant GISTs contain more immune cells than KIT-mutant GISTs.
This suggests that patients with PDGFRA-mutant GIST may ultimately have a greater potential to respond to immunotherapy.
Through differential gene expression analysis, we identified mutation specific immune landscapes that may be significant for directing GIST immunotherapy. First, It is clear, however, that in cancers with a high number of mutations, tumor mutational burden correlates with immunotherapy response (33) . However, the role of neoepitopes in the immune response of cancers with a single, oncogenic mutation (i.e., GIST) has not been described. To our surprise, nearly every GIST mutation in our cohort produced a neoepitope capable of binding with high-affinity to patient-specific HLA Class I, suggesting that even cancers with one mutation can generate a neoepitope recognizable by the immune system. We discovered that the D842V mutation produced 6 different high affinity neoepitopes, which bound to 12 different HLA types of patients in this cohort alone, one of which is the most common HLA type in the United States and in Caucasians (35, 36 ). While we have not shown that these neoepitopes produced an immune response in these patients, it is intriguing that GISTs with a larger immune infiltrate appear to have a mutation that generates peptides with broad HLA binding specificity, suggesting that this mutation may be of higher quality (37) . Moreover, the HLA-specific binding affinities of neoepitopes generated by mutation-specific GIST subtypes reported in this study may provide a road map for patient selection in future neoantigen vaccination trials.
PDGFRA-mutant
We employed machine learning in order to identify key differences and to profile the expression of immune-related genes between PDGFRA and KIT-mutant GISTs.
Generating a gene-expression based immune-profile which accurately predicted the KIT or PDGFRA-mutant genotype not only supports our hypothesis that the genotype may impact the immune infiltrate, but also introduces another method by which profiling the immune landscapes of KIT and PDGFRA-mutant tumors can lead to more personalized cancer immunotherapy. Not surprisingly, CXCL14 appeared to be a top feature of PDGFRA-mutant GIST, again suggesting that CXCL14 expression is oncogene-specific and may be responsible for the observed differences in immune infiltration and activity.
TGFBR1, TNFSF9, MICA, TNFRSF25, CD96, IDO, TNFSF14, KDR, and TNFRSF9 all contributed to the predictive capacity of the immune profiling models, which resulted in >90% diagnostic accuracy in our testing set and in 83% of the CINSARC validation set.
We have previously shown the importance of IDO in dictating the immune phenotype of GIST (13) . The role of NK cells and the additional immune modulatory receptors identified in this study should continue to be explored.
Since immunotherapy has not yet shown efficacy in advanced and metastatic
GIST (48), we sought to explore the immune profiles of PD-1 high and PD-L1 high GISTs across our entire GIST cohort to identify both therapeutic opportunities and potential barriers to effective immunotherapy. CD27 was found to be a significant feature predictive of high PD-1 expression in our random forest model, which correctly identified high PD-1 expression in 93% of our testing GIST cohort. Agonistic CD27 antibodies already exist and have shown efficacy with anti-PD-1 in other models, suggesting that this may be an effective strategy for GIST (49) . Similarly, the costimulatory and checkpoint receptors CD40 and BTLA, along with the immune checkpoint ligand PDCD1LG2 and the MHC I protein MICB were features predictive of high PD-1 expression. We have previously shown that CD40 ligation enhances antitumor immunity in our Kit exon 11 mouse model (17) , and these other receptors should be considered in future trials.
Notably, applying our PD-1 model to the external CINSARC cohort only resulted in 67% accuracy, even though our PD-L1 model, in which the same methodology was used, was more accurate (92%). One reason may be related to the small sample size of the external cohort. However, these models identify high-priority targets for further experimental validation.
Finally, expression of key antigen presenting machinery including B2M, PDCD1LG2, HLA-DRA, and TAP was found to be highly predictive of PD-L1 expression not only in our cohort (86% accuracy) but also in the external CINSARC GIST cohort (92% accuracy), suggesting a tumor-cell specific mechanism of linking neoepitope presentation with immune suppression. A similar finding has been observed in HIV infected cells, where MHC class I machinery was upregulated concurrently with PD-L1 (50). This is an important concept to consider, as efforts to block PD-L1 may result in tumor cell changes that also downregulate MHC class I antigen presentation, which is essential for the CD8 T cell-mediated immune response. High PD-L1 expression has also recently been shown to independently correlate with a worse prognosis in soft tissue sarcomas, which was attributed to an increased degree of immune exhaustion, suppression, and negative regulation (51) . In contrast, efforts to enhance antigen presentation using neoantigen peptide vaccination or GM-CSF-expressing tumor cell vaccines may require PD-L1 inhibition.
Ultimately, it is becoming increasingly evident that immunotherapy requires a specific approach targeted not only to the tumor type but also the tumor-specific immune microenvironment. Through RNA sequencing and four trained machine learning models, we have characterized important and consistent differences in the immune landscape of GISTs driven by different oncogenic mutations, which we believe may help guide future immunotherapy trials in GIST.
Materials and Methods
Human GIST specimens and clinicopathologic features. Fresh surgical specimens were collected immediately upon resection and flash frozen in liquid nitrogen. RNA was extracted using the RNeasy kit (Qiagen) as per the kit-specified protocol.
Clinicopathologic features were obtained via chart review of patient and pathologic records. human genome (version hg38_r88) and gene-level counts were calculated using STAR version 2.6.0a (53) . Read counts were then normalized and differential gene expression (DGE) analyses were performed on indicated groups using the R software package DESeq2 (54, 55) . Gene set enrichment analysis (GSEA) was performed using the java GSEA software package (version 3.0) and the molecular signature databases (MSigDB) version 6.2 from the Broad Institute (56, 57) .
The activity of cytotoxic T-cells within each sample was estimated utilizing the CYT score, which is calculated from the geometric mean of the normalized read counts for Perforin (PRF1) and Granzyme A (GZMA) as previously described (23) . The immune cell compartment of these samples was further quantified from the normalized read counts using the R package ESTIMATE (23) . The ESTIMATE algorithm is composed of a non-immune "stromal score" parameter and an "immune score" parameter. In this work, we refer to ESTIMATE score as the "immune score" subcomponent of the ESTIMATE algorithm, which infers the degree of immune cell infiltration within tumor tissue based on expression data of 141 immune-related genes previously shown to correlate with the presence of leukocytes (24) . The absolute quantities of individual immune cell subtypes was inferred from the normalized read counts by using the CIBERSORT program (29) , which employs an externally-validated leukocyte gene signature matrix (LM22) of 547 genes designed to distinguish 22 cell phenotypes including seven T cell types, B cells, macrophages, monocytes, and NK cells (29) .
Heatmaps of gene expression data with corresponding clinicopathologic characteristics were created with the R package ComplexHeatmap (58) . Single sample gene set enrichment analyses (ssGSEA) were performed using the R software package GSVA (59).
Neoepitopes and HLA prediction. Patient HLA haplotypes were inferred using the program Seq2HLA (60). For neoepitope identification, the amino acid sequences of patient-specific mutations were mapped to combinations of 8-, 9-, and 10-mer peptides, with the mutation evaluated at each amino acid position. Each patient-specific peptide was then tested with the respective patient-specific HLA-type using NetMHCPan3.0 to identify potential high affinity neoepitopes (61, 62) . Neoepitope burden was defined as any epitope with a predicted binding affinity within the top 2% when compared to 400 random natural peptides, as recommended by NetMHCPan3.0. High affinity neoepitopes were further filtered using a binding affinity threshold of 500nm, while very high affinity neoepitopes were defined as <150nM binding affinity. Finally, to explore mutation-specific neoepitope binding diversity, mutation-specific neoepitopes were tested more broadly against all validated NetMHCPan3.0 HLA-types and visualized using heatmap.2 in R.
Machine learning. Random forest modeling with 5-fold cross validation was performed on the training set using the software package caret for R to identify top predictors (38) .
One hundred and seventeen features, comprising normalized read counts of various immune genes and bioinformatically inferred CIBERSORT scores were used to train the model (Supplemental Table 5 ). For characterization of PDGFRA-specific immune features, KIT and PDGFRA-mutant GIST samples were first partitioned randomly into training (80% of samples) and testing sets (20% of samples). The training data set was used to train a random forest machine learning classifier using 5-fold cross validation.
During each of the 5 folds, a random forest model was trained on 80% of the training data, and training accuracy, sensitivity, and specificity was calculated; the remaining 20% of the training data was then used to calculate testing accuracy, sensitivity and specificity. Finally, our trained, machine learning model was applied to the hold-out, 20% testing set and to the external validation CINSARC cohort (n=12, (39)) in order to assess model accuracy on a naïve sample set.
Given the total sample size of our cohort and to prevent overfitting of our model, random forest modeling with 5-fold cross validation was re-performed on the training set using only the top 6 identified features, and the model was then applied to the naïve testing set and CINSARC external data set to assess for model accuracy. Feature "Importance" is a variable calculated by the caret package, with a higher number indicating that the feature is more important for model accuracy (38) . The confusion matrices shown in Figures 6 and 7 reflect the model with the highest accuracy after 5-fold cross validation and optimization by caret. The p-value used by caret is calculated using an exact binomial test in which a one-sided test is performed to see if the model accuracy rate is better than the "no information rate," which represents the proportion of data within the majority class. For generation of PD-1 and PD-L1-specific immune features, the same approach was used, with groups split into high and low expression based on median PD-1 (median=14.1) or PD-L1 (median=209.5) normalized read counts in the training set.
Quantitative real-time PCR. Total RNA was extracted from snap-frozen human tumors, reverse transcribed, and amplified with PCR TaqMan probe for CXCL14 (Hs01557413_m1). Quantitative PCR was performed using a ViiATM7 real-time PCR system (Applied Biosystems). Data were calculated by the 2 -ΔΔCt method as described by the manufacturer's protocol and were expressed as fold increase over the GIST-T1
or GIST-882 cell line control (63, 64) . 
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Primary vs Metastatic
Primary Metastatic Single sample Gene Set Enrichment Analysis (ssGSEA) of 75 GIST specimens, organized by mutational driver and increasing ESTIMATE score. Unsupervised row clustering grouped gene sets into three major categories based on cell cycle pathways, metabolic pathways, and immune pathways. Clinicopathologic characteristics of the 75 GIST specimens are shown in the annotation above the heat map and in Supplemental Table 1 . 
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